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Abstract: Diagnostic studies of accuracy targeting sensitivity and specificity are commonly done in a paired design 
in which all modalities are applied in each patient, whereas cost-effectiveness and cost-utility analyses are usually 
assessed either directly alongside to or indirectly by means of stochastic modeling based on larger randomized con-
trolled trials (RCTs). However the conduct of RCTs is hampered in an environment such as ours, in which technology 
is rapidly evolving. As such, there is a relatively limited number of RCTs. Therefore, we investigated as to which extent 
paired diagnostic studies of accuracy can be also used to shed light on economic implications when considering a 
new diagnostic test. We propose a simple decision tree model-based cost-utility analysis of a diagnostic test when 
compared to the current standard procedure and exemplify this approach with published data from lymph node 
staging of prostate cancer. Average procedure costs were taken from the Danish Diagnosis Related Groups Tariff in 
2013 and life expectancy was estimated for an ideal 60 year old patient based on prostate cancer stage and prosta-
tectomy or radiation and chemotherapy. Quality-adjusted life-years (QALYs) were deduced from the literature, and an 
incremental cost-effectiveness ratio (ICER) was used to compare lymph node dissection with respective histopatho-
logical examination (reference standard) and 18F-fluoromethylcholine positron emission tomography/computed to-
mography (FCH-PET/CT). Lower bounds of sensitivity and specificity of FCH-PET/CT were established at which the 
replacement of the reference standard by FCH-PET/CT comes with a trade-off between worse effectiveness and 
lower costs. Compared to the reference standard in a diagnostic accuracy study, any imperfections in accuracy of a 
diagnostic test imply that replacing the reference standard generates a loss in effectiveness and utility. We conclude 
that diagnostic studies of accuracy can be put to a more extensive use, over and above a mere indication of sensitiv-
ity and specificity of an imaging test, and that health economic considerations should be undertaken when planning 
a prospective diagnostic accuracy study. These endeavors will prove especially fruitful when comparing several 
imaging techniques with one another, or the same imaging technique using different tracers, with an independent 
reference standard for the evaluation of results.
Keywords: Diagnostic study, accuracy study, sensitivity, specificity, cost-effectiveness, molecular imaging, 
positron-emission tomography/computed tomography, 18F-fluoromethylcholine, prostate cancer, staging
Introduction 
In diagnostic research, imaging techniques are 
required to detect and localize disease and, 
thereby, to discriminate between diseased and 
disease-free (or metastasized and metastasis-
free) patients by means of sensitivity and speci-
ficity. Diagnostic research in recent decades 
has been affected by the introduction and 
increased clinical use of rapidly evolving imag-
ing techniques like single-photon emission 
computed tomography (SPECT), magnetic reso-
nance imaging (MRI), positron emission tomog-
raphy (PET), PET/computed tomography (PET/
CT), and, most recently, PET/MRI. Sufficient 
sensitivity and specificity of a test is, though, 
not considered appropriate as surrogate end-
point for clinical benefit which preferably has to 
be demonstrated by means of randomized con-
trolled trials (RCT) in which mortality, morbidity, 
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symptoms, and quality of life are measured [1, 
2]. Ideally, analyses examining societal costs 
and benefits of a given diagnostic imaging tech-
nology complete the picture [3].
Cost-effectiveness analysis (CEA) compares 
alternative interventions using costs and a 
common effectiveness measure (e.g., correct 
staging or life-years gained). The results of such 
comparisons may be stated in terms of costs 
per unit of effectiveness (e.g. dollars spent per 
life-year gained) or effectiveness per unit of 
cost (life-years gained per dollar spent). In this 
context, the relative cost-effectiveness of alter-
native tests can be assessed as long as the 
alternatives under consideration are not of an 
exceptionally different scale. In cost-utility anal-
ysis (CUA), the incremental cost of an interven-
tion is compared to the incremental health 
improvement attributable to the intervention, 
where health improvement is for instance mea-
sured in quality-adjusted life-years (QALYs) 
gained [4-6].
Studies demonstrating clinical benefit by 
improvement of long-term patient outcome as 
well as studies on cost-effectiveness or cost-
utility do require RCTs in order to compare 
imaging techniques head-to-head. However, 
studies of this type are rare [7-9] and most of 
the studies in diagnostic research today are 
still diagnostic accuracy studies. An alternative 
approach to RCTs is the application of econom-
ic modeling techniques.
Economic modeling is a relatively cheap and 
effective way of synthesizing existing data and 
evidence available on the costs and outcomes 
of alternative interventions [10-13]. In interven-
tion trials, for instance, intervention thresholds 
were introduced as the absolute threshold of 
disease risk at which intervention becomes 
acceptable in terms of both efficacy and cost-
effectiveness [14, 15].
We propose to utilize simple diagnostic studies 
of accuracy to assess the incremental cost-
effectiveness ratio (ICER) for the comparison of 
a (new) diagnostic imaging technique and a ref-
erence standard diagnostic procedure. Com- 
pared to the reference standard, any imperfec-
tions in accuracy of a new diagnostic imaging 
technique will indeed imply that replacing the 
reference standard generates a loss in effec-
tiveness. However, lower boundaries of sensi-
tivity and specificity of a new imaging test can 
be assessed at which the replacement of a 
standard procedure by the new test comes with 
a trade-off between worse effectiveness and 
lower costs. We demonstrate our approach by 
using data from a recent investigation at our 
institution in which the value of 18F-fluorome- 
thylcholine (FCH) PET/CT for lymph node stag-
ing in prostate cancer was assessed using pel-
vic lymph node dissection (LND) with subse-
quent histological examination as the reference 
standard [16].
Methods
Background on clinical study
The methodology of the clinical study was pub-
lished earlier [16]. In brief, between January 
2008 and December 2010 FCH-PET/CT was 
performed in 210 intermediate or high risk 
patients prior to regional LND and subsequent 
histological examination (reference standard). 
The surgical technique comprised an open ret-
roperitoneal bilateral pelvic LND that was 
undertaken through a midline incision, either 
as part of the radical prostatectomy or as an 
individual operation. The LND was performed 
along the medial side of the external iliac ves-
sels from the femoral canal up to the bifurca-
tion of the internal and external iliac vessels, 
including the obturator fossa. The LND included 
most of the lymph nodes of the external iliac, 
obturator, and hypogastric nodes. The speci-
mens were prospectively mapped according to 
their anatomical location and processed 
according to standard protocols for the subse-
quent histological examination. The result of 
the histological examination of the lymph nodes 
was compared with the result of FCH-PET/CT, 
as obtained by blinded review. Sensitivity and 
specificity of FCH-PET/CT for the detection of 
lymph node metastases were estimated to be 
0.73 (Wilson score-based 95% confidence 
interval (95% CI): 0.58-0.84) and 0.88 (95% CI: 
0.82-0.92), respectively.
Cost data collection
Cost data were collected post hoc in addition to 
the clinical trial. These comprised costs for 
lymph node dissection, histological examina-
tion of lymph nodes, prostatectomy, radiation 
and chemotherapy as per the Danish Diagnosis 
Related Groups Tariff in 2013. Details can be 
found in Table 1.
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Table 1. Calculation of average cost and QALYs, depending on the outcome of the imaging procedure. One-hundred DKK correspond to 17.11 
US$ (daily exchange rate on October 29, 2014)
Dissection of lymph nodes and histopathological 
examination (reference standard) FCH-PET/CT
Result of diagnostic procedure Positive Negative True positive False negative False positive True negative
Lymph node dissection 32,859 DKK 32,859 DKK
Histopathological examination 1,500 DKK 2,250 DKK
FCH-PET/CT scan 11,110 DKK 11,110 DKK 11,110 DKK 11,110 DKK
Radiation and chemotherapy 276,413 DKK 276,413 DKK 276,413 DKK 389,586 DKK
Prostatectomy 60,026 DKK 60,026 DKK 60,026 DKK
Sum 310,772 DKK (53,171 $) 95,135 DKK (16,277 $) 287,523 DKK (49,193 $) 347,549 DKK (59,463 $) 400,696 DKK (68,556 $) 71,136 DKK (12,171 $)
QALYs 4.2 19.5 4.2 3.8 9.0 19.5
Cost-utility analysis in simple diagnostic studies of accuracy
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Life-expectancy and QALYs
The expected number of life years remaining 
was estimated for a 60 year old patient and 
depended on the stage of disease as indicated 
by the diagnostic imaging procedure. The fol-
lowing numbers were not explicitly available 
and were deduced from the literature to the 
best of our knowledge [17-20]:
● True positive (metastatic prostate cancer, 
radiation and chemotherapy): 8 years.
● False negative (metastatic prostate cancer, 
prostatectomy): 8 years.
● False positive (localized prostate cancer, 
radiation and chemotherapy): 14 years.
● True negative (localized prostate cancer, 
prostatectomy): 20.4 years.
QALYs, i.e., (score per year) x (expected number 
of life years), for these four outcomes of the 
diagnostic staging procedure were also not 
explicitly available and instead deduced from 
the literature to the best of our knowledge [21-
castration, one year of moderate other disease, 
one year of heavy other disease.)
● True negative: 0.9 × 2 + 1 × 17 + 0.5 × 1.4 = 
19.5 QALYs. (Two years of discomfort due to 
treatment, but knowledge of being cured, sev-
enteen life years in good health, 1.4 years of 
other disease). 
ICER
We observed a prevalence for progressed dis-
ease (malignant metastases in the lymph 
nodes) in 41 (19.5%) of the 210 patients in our 
clinical study [16]. We modeled the alternative 
pathways by means of a decision tree (Figure 1) 
and evaluated the expected cost and expected 
utility for both FCH-PET/CT and the reference 
standard accordingly (Table 2), given the esti-
mated sensitivity and specificity of FCH-PET/CT 
of 0.73 and 0.88, respectively. The ICER is then 
the ratio between the difference in expected 
cost and the difference in expected utility (FCH-
PET/CT minus reference standard).
Apart from abovementioned primary analysis in 
which the point estimates for sensitivity and 
Figure 1. Decision tree model for the detection of lymph node metastases. 
The estimated prevalence of 0.195 as well as estimates of sensitivity and 
specificity of FCH-PET/CT stem from the clinical study [16].
24]. Scores were estimated 
using values between one 
(good health) and zero (death):
● True positive: 0.7 × 5 + 0.4 
+ 0.2 + 0.1 = 4.2 QALYs. (Five 
years of mild disease includ-
ing consequences of castra-
tion, one year of moderate 
disease, one year of heavy 
disease, one year near death.)
● False negative: 0.8 × 2 + 
0.5 × 3 + 0.4 + 0.2 + 0.1 = 
3.8 QALYs. (Two years of dis-
ease including consequences 
of treatment and disease, 
three years of mild disease 
including further treatment 
and consequences of castra-
tion, one year of moderate 
disease, one year of heavy 
disease, one year near death.)
● False positive: 0.7 × 12 + 
0.4 + 0.2 = 9.0 QALYs. (Twelve 
years of mild disease includ-
ing belief of metastatic dis-
ease and consequences of 
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specificity of FCH-PET/CT from our clinical study 
were used, we assessed lower boundaries of 
sensitivity and specificity of FCH-PET/CT at 
which the replacement of the reference stan-
dard comes with a trade-off between worse 
effectiveness and lower costs. This was done 
by varying the levels of sensitivity and specific-
ity of FCH-PET/CT in the ICER calculations. 
These boundaries were then compared to the 
95% CI of sensitivity and specificity from our 
clinical study.
All analyses were performed using SAS 9.1.3 
(SAS Institute Inc., Cary, NC, USA) and Stata/
MP 13.1 (StataCorp, College Station, TX, USA).
Results
The ICER was -10,760 DKK (-1,841 $) per QALY 
as the difference in expected cost and the dif-
ference in expected utility (FCH-PET/CT minus 
reference standard) was 11,138 DKK (1,906 $) 
and -1.0351 QALY, respectively (see also Figure 
1 and Table 2). This means that FCH-PET/CT 
was, given the estimated values of sensitivity 
and specificity of 0.73 and 0.88, respectively, 
both more costly and less effective in terms of 
QALYs than the reference standard. Figure 2 
shows the cost-effectiveness plane, in which 
the abovementioned ICER value of -10,760 
DKK (-1,841 $) per QALY corresponds to the 
point P1 in quadrant II. Points in the four quad-
rants have the following interpretation:
● I: FCH-PET/CT is more effective (in terms of 
QALYs), but also more costly than LND staging.
able ICER for which a hypothetical value of 
30,000 $ per QALY was assumed here. Line K 
divides the plane into cost-effective (lower 
right) and non-cost-effective outcomes (upper 
left). 
When varying the levels of sensitivity and speci-
ficity of FCH-PET/CT, it was found that the spec-
ificity of FCH-PET/CT must be at least 0.92 in 
order to change the sign of the ICER to be posi-
tive, meaning here that losses in terms of QALYs 
were accompanied by monetary savings when 
moving from the reference standard to FCH-
PET/CT. For specificities of 0.92, 0.93, 0.94, 
and 0.95, the sensitivities needed to exceed 
0.78, 0.55, 0.33, and 0.10, respectively, in 
order to get a positive number as ICER (see 
filled circles and squares in Figure 3). For 
instance, the pair (sensitivity, specificity) = 
(0.78, 0.92) was associated with a difference in 
expected cost and a difference in expected util-
ity of -57 DKK (-9.75 $) and -0.693 QALY, 
respectively, resulting in an ICER of 82 DKK 
(14.03 $) per QALY. This value is indicated by 
point P2 in Figure 2 and still reflects a non-
cost-effective result at an ICER benchmark 
value of 30,000 $ per QALY. 
The abovementioned lower boundaries of sen-
sitivity and specificity of FCH-PET/CT imply a 
trade-off between worse effectiveness and 
lower costs when replacing the reference stan-
dard with FCH-PET/CT. Comparing these bound-
aries to the 95% CIs of sensitivity and specifici-
ty of PET/CT from our clinical study showed that 
only some values from the upper range of these 
Table 2. Calculation of expected cost and expected utility for FCH-PET/
CT and the reference standard, according to the decision tree model in 
Figure 1. One-hundred DKK correspond to 17.11 US$ (daily exchange 
rate on October 29, 2014)
Pathway Probability Cost (DKK) Expected cost (DKK) Utility Expected utility
A 0.195 310,772 60,675 4.2 0.82
B 0 371,548 0 3.8 0
C 0.805 95,135 76,561 19.5 15.69
D 0 423,945 0 9 0
Total 1 137,236 16.51
E 0.143 287,523 40,979 4.2 0.60
F 0.053 347,549 18,321 3.8 0.20
G 0.708 71,136 50,378 19.5 13.81
H 0.097 400,696 38,696 9 0.87
Total 1 148,374 15.48
● II: FCH-PET/CT is less 
effective and more cost-
ly than LND staging, i.e. 
LND staging dominates 
FCH-PET/CT.
● III: FCH-PET/CT is less 
effective, but also less 
costly than LND staging.
● IV: FCH-PET/CT is more 
effective and less costly 
than LND staging, i.e. 
FCH-PET/CT dominates 
LND staging.
The blue line K indicates 
the maximum accept-
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95% CIs (i.e. a specificity of 0.92 and a sensitiv-
ity between 0.78 and 0.84; see filled squares in 
Figure 3) were accompanied by worse effec-
tiveness at lower costs when replacing the ref-
erence standard with FCH-PET/CT. Figure 4 
shows a contour plot which illustrates an 
increasing ICER with increasing sensitivity and 
specificity of FCH-PET/CT. The orange area indi-
cates combinations of sensitivity and specifici-
ty at which the ICER is negative, hence indicat-
ing both lower costs and superior effectiveness 
of the reference standard over FCH-PET/CT. 
This area accords to the area of unfilled circles 
and squares in Figure 3. The remaining, i.e. 
non-orange, area in Figure 4 shows combina-
tions of sensitivity and specificity at which the 
ICER was positive, thereby indicating lower 
costs of FCH-PET/CT, but favorable utility for 
the reference standard. Due to the prevalence 
of progressed disease (19.5%) and its impact 
on cost calculations (Figure 1, Table 2), even 
pairs with relatively low sensitivity, but high 
specificity, were associated with a positive 
ICER. Only the dark blue area indicates combi-
nations of sensitivity and specificity at which 
the replacement of LND staging by FCH-PET/CT 
would be cost-effective, given an ICER bench-
mark value of 30,000 $ per QALY (see, for 
instance, point P3 in Figure 2).
Discussion
The assessment of the cost-effectiveness or 
the cost-utility of diagnostic imaging techniques 
like PET/CT does, in principle, require larger 
scale clinical trials. Such trials are difficult to 
conduct in an environment in which technology 
is rapidly evolving and costly. RCTs that also 
evaluate cost-effectiveness or cost-utility rep-
resent a study design scarcely found in clinical 
trials that evaluate non-invasive imaging 
modalities [27, 28]. Moreover, not many cost-
effectiveness analyses for PET/CT were under-
taken in cancer imaging prior to 2010 [29, 30]. 
Recent systematic reviews on the cost-effec-
tiveness of PET and PET/CT in cancer and non-
cancer indications and of 18F-Fluorodeoxyglu- 
cose PET in tumors other than lung cancer 
Figure 2. Cost-effectiveness plane (adapted from [25] (p.212) and [26] (p.12)). The blue line K divides the plane into 
cost-effective (lower right: I A, III B, IV) and non-cost-effective areas (upper left: I B, II, III A). Here, line K is based on 
a hypothetical benchmark value of 30,000 $ per QALY. 
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Figure 3. Indication of pairs (sensitivity, specificity) for which the expected cost and the expected utility of FCH-PET/CT were greater than and less than those of the 
reference standard, respectively, thereby implying a negative ICER (unfilled circles and squares) and for which both the expected cost and the expected utility of 
FCH-PET/CT were less than those of the reference standard, yielding a positive ICER (filled circles and squares). The estimated values of sensitivity and specificity 
of FCH-PET/CT from our clinical study and the respective 95% confidence intervals are shown (squares). The prevalence of malignant lymph node metastases was 
0.195 [16].
Cost-utility analysis in simple diagnostic studies of accuracy
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comprised only 47 and 16 studies, respectively 
[28, 31]. Modeling techniques remain the way 
to proceed in generating and synthesizing the 
economic evidence efficiently in order to inform 
decision makers regarding PET [32]. 
Our approach is a simple, applied example of a 
cohort model-based cost-utility analysis of a 
diagnostic test for lymph node staging of pros-
tate cancer in which we take the perspective of 
the hospital. The model is essentially a deci-
sion tree, with crude life expectancy estimates 
for each endpoint. It does not replace the 
assessment of cost-effectiveness or cost-utility 
in clinical trials by means of more sophisticated 
stochastic modeling or, whenever possible, in 
addition to RCTs. However, facing scarce evalu-
ative resources, we propose an extended use 
of simple diagnostic studies of accuracy. An 
evaluation of lower boundaries of sensitivity 
and specificity at which the replacement of the 
reference standard comes with a trade-off 
between worse effectiveness and lower costs 
is easily performed and gives valuable insight 
into the potential economic burden caused by 
new diagnostic procedures. Obviously, these 
lower economic thresholds of sensitivity and 
specificity must also be assessed from a clini-
cal point of view, not just an economical one, 
as, for instance, only relatively large values of 
sensitivity and specificity of FCH-PET/CT will 
support the replacement of lymph node dissec-
tion by FCH-PET/CT scanning in the future. In 
our example, the former clinical study results 
indicated that from a clinical point of view FCH-
PET/CT was not sufficiently accurate to replace 
the reference procedure. This post hoc cost-
effectiveness assessment pointed to values at 
the upper range of the 95% CI of accuracy mea-
sures (i.e. a specificity of 0.92 and a sensitivity 
between 0.78 and 0.84) at which worse effec-
tiveness at least comes along with lower costs 
when replacing the reference standard with 
FCH-PET/CT.
The histological examination of the lymph 
nodes in our clinical study [16] was done 
according to standard protocols. Later, fellow 
Figure 4. ICER of FCH-PET/CT in prostate cancer patients depending on varying levels of sensitivity and specificity. 
One-hundred DKK correspond to 17.11 US$ (daily exchange rate on October 29, 2014). The prevalence of malignant 
lymph node metastases was 0.195 [16].
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colleagues of ours reinvestigated the lymph 
nodes from all 169 patients of whom the lymph 
nodes were judged to be negative in the stan-
dard examination by means of an extended 
pathological examination, which is a costly and 
time-consuming procedure [33]. The extended 
pathological examination included a 100-μm 
deep haematoxylin and eosin (HE) section fol-
lowed by a slide stained with cytokeratin AE1/
AE3 and then by four HE sections at 0.5-mm 
intervals. The standard pathological examina-
tion detected 41 patients with malignant lymph 
node involvement, whereas the extended path-
ological examination revealed 5 additional 
patients with lymph node metastases. This 
means that the sensitivity of the reference pro-
cedure in our example could be assessed as 
low as 89.1%, whereas it is still reasonable to 
assume a specificity of the reference proce-
dure of 100%. Then, the lower boundaries of 
sensitivity and specificity at which the ICER 
becomes positive decrease slightly to the pairs 
(sensitivity, specificity) = (0.90, 0.91), (0.67, 
0.92), (0.44, 0.93), and (0.22, 0.94), thereby 
comprising additional pairs from the estimated 
95% CI of sensitivity and specificity of FCH-PET/
CT as compared to assuming the reference 
standard to be perfect. Besides, sensitivity and 
specificity of FCH-PET/CT need also to be reas-
sessed on these grounds (here, a reclassifica-
tion of these 5 patients would actually lead to a 
slightly decreased sensitivity of 0.67 (95% CI: 
0.53-0.79), whereas specificity remains unch- 
anged). The consequence of assuming an 
imperfect reference procedure is a larger num-
ber of sensitivity/specificity pairs for which 
switching to a new imaging test could be of 
interest from an economical point of view and 
emphasizes the outstretched reach of the valid-
ity of the reference standard on both the accu-
racy and the cost-effectiveness assessment of 
competing tests.
PET/CT is a technology that is rapidly evolving 
and continually improving, most likely resulting 
in improved sensitivity and specificity of any 
given tracer. As a consequence, any prediction 
of the economic burden of PET/CT will either 
hold (when sensitivity and specificity are not 
subjected to significant change despite techno-
logical advancement) or will be overestimated, 
i.e., a conservative estimation, when re-visited 
later (when sensitivity and specificity actually 
are subjected to significant improvements due 
to technological advancement). According to 
this, any economic assessment today can be 
considered a lower boundary of the actual eco-
nomic burden tomorrow when technology has 
improved since the economic assessment.
Limitations of our study comprise its retrospec-
tive nature, working with a base-case scenario 
of a typical 60 year old patient only, and the 
extent to which costs and QALYs were assessed 
post hoc, failing to comprise ranges for both 
costs and QALYs and merely using point esti-
mates instead, thereby failing to provide sup-
plementary sensitivity analyses. Using fixed 
values does, indeed, influence the calculated 
numbers, but not necessarily the principles 
applied. Further limitations of our study are the 
relatively short time horizon, the disregard of 
some form of discounting of costs and benefits 
in order to consider their present value, and the 
hospital perspective that we take rather than a 
more societal point of view. We did not consider 
side effects of LND, radiation and chemothera-
py, or prostatectomy which entails an over-sim-
plification of the clinical setting. All in all, the 
ICER and, thereby, the concrete lower boundar-
ies of sensitivity and specificity derived depend 
heavily on our assumptions made. However, we 
would like to stress the added value of our 
approach in principle and do not claim robust-
ness of the derived lower boundaries of sensi-
tivity and specificity against model variations.
Future research on the added value of cost-
utility analysis in diagnostic studies of accuracy 
in other clinical settings will improve our 
approach by bearing the following issues in 
mind:
● Tariff-based cost estimation is far from actual 
costs; costs should be, whenever possible, 
estimated using claims data or accounted 
costs on a per-patient basis in order to enable 
the assessment of cost distributions across 
patients and patient groups. However, tariff-
based cost data may be the only available 
source in countries like Denmark. 
● Instead of using fixed values of point 
estimates for costs, life years, or utility index, 
ranges should be applied. Costs differ greatly 
between different age groups/cancer stage 
groups, those who received different diagno-
sis/treatment options, or those with and with-
out operative complications. Also life-years 
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vary greatly. At least, 95% CI for the mean value 
of costs/life years should be applied to the 
cost-utility sensitivity analysis. 
● Quality of life scores in a healthy population 
typically average around 0.85 on a scale of 0 to 
1. Even an advanced stage group of patients 
rarely score, on average, less than 0.3. If suit-
able literature on the long-term quality of life of 
patients’ post-diagnostic tests is not available, 
looking beyond the cancer form under consid-
eration to other cancers may prove beneficial in 
order to get an idea of average quality of life 
scores. Expert elicitation can then be used to 
adjust these scores depending on how the can-
cer form under consideration is felt to differ.
● The derivation of a utility index by measuring 
patients’ preferences is, generally speaking, a 
challenging endeavour and methods used are 
various (e.g. Visual Analogue Scale, time trade-
off, or standard gamble). Cost-effectiveness 
analysis using clinical endpoints such as sur-
vival or time-to-progression as effectiveness 
measures is probably easier to convey to clini-
cians and policy makers as it makes use of 
more direct measures of patient-benefit, being 
independent of patient preferences and the 
measurement thereof. 
● Probabilistic sensitivity analysis sheds light 
on the implications of the uncertainty of the 
model by investigating the consequences of 
choosing alternative, plausible values for quali-
ty of life scores, survival, cost of treatment, 
starting age of the population in the model, and 
the results of the diagnostic imaging test.
● A cost-effectiveness threshold by means of a 
benchmark ICER value is needed to get context 
of what QALY benefit would have to be seen to 
make a diagnostic imaging test cost-effective. 
The ICER is of little value without it and the risk 
is that international thresholds are then consid-
ered that might not be representative for the 
country to which the respective study results 
are supposed to apply.
In 2013, Consolidated Health Economic Eva- 
luation Reporting Standards (CHEERS) were 
published in order to consolidate and update 
former health economic evaluation guidelines 
into one current, useful reporting guidance doc-
ument, including a 24-item checklist [34].
Conclusions
Simple diagnostic studies of accuracy can be 
put to a more extensive use, over and above a 
mere indication of sensitivity and specificity of 
an imaging test. An evaluation of lower bound-
aries of sensitivity and specificity can be per-
formed and gives valuable insight into the eco-
nomic burden of new diagnostic procedures or 
tracers. Compared to the reference standard in 
a diagnostic accuracy study, any imperfections 
in accuracy of a diagnostic test imply that 
replacing the reference standard generates a 
loss in effectiveness and utility. In our example, 
substituting the conventional staging proce-
dure with FCH-PET/CT would produce a loss, 
and not a minor one, due to the clinically ineffi-
cient sensitivity and specificity of FCH-PET/CT. 
Giving our study’s limitations, we cannot claim 
cost-effectiveness of FCH-PET/CT in staging 
prostate cancer, but we have hopefully stimu-
lated further perspectives to the planning and 
evaluation of simple diagnostic studies of 
accuracy. 
We focused on the comparison of a non-inva-
sive imaging technique and the current, inva-
sive reference procedure in that respective 
indication. Analogously, cost-utility and cost-
effectiveness analyses using ICERs can and 
should be done especially in paired diagnostic 
studies of accuracy when comparing several 
imaging techniques with one another, or the 
same imaging technique using different trac-
ers, with an independent reference standard 
for the evaluation of results. This will enable to 
rank order several different imaging techniques 
from an economical point of view, supplement-
ed by a graphical display by means of a cost-
effectiveness plane, which completes the pic-
ture on top of the imaging techniques’ clinical 
assessments. Health economic considerations 
should be undertaken when planning any pro-
spective diagnostic accuracy study in order to 
investigate if adding cost-utility or cost-effec-
tiveness analysis to sensitivity and specificity 
determination of diagnostic tests improves the 
ability to identify the better performing alterna-
tive between competing diagnostic modalities 
when each are referenced to a gold standard. 
Cost-utility and cost-effectiveness analyses 
involve various challenges. However, modalities 
(or tracers) that also seem to be economically 
Cost-utility analysis in simple diagnostic studies of accuracy
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defensible will be easier to argue for when it 
comes to regular use in daily clinical practice 
(such as in Denmark) or reimbursement (such 
as in the US or Germany).
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